PB
SWTX

Pinnacle Bancorp’s SpringWorks Therapeutics SWTX Stock Holding History

Pinnacle Bancorp’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-102
Closed -$2.63K – 806
2023
Q1 		$2.63K Buy
+102
New +$2.98K ﹤0.01% 758

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Pinnacle Bancorp's SWTX Position: Q2 2023 in Review

Pinnacle Bancorp sold out of SpringWorks Therapeutics (SWTX) in Q2 2023, closing a stake of 102 shares — an estimated $2.63K sold.

Pinnacle Bancorp first reported a position in SWTX in Q1 2023 and held it in 1 quarter. The position peaked at $2.63K in Q1 2023. 142 funds tracked by Wall St. Rank hold SWTX as of Q2 2023.

  • Pinnacle Bancorp reported no remaining SpringWorks Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Pinnacle Bancorp sold 102 SpringWorks Therapeutics shares in Q2 2023, an estimated $2.63K.
  • Pinnacle Bancorp first reported a position in SpringWorks Therapeutics in Q1 2023 and held it in 1 quarter.
  • Pinnacle Bancorp's SpringWorks Therapeutics position peaked at $2.63K in Q1 2023.
  • 142 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2023.

Based on Pinnacle Bancorp's 13F filing for Q2 2023, filed 14 Jul 2023.